About
We will develop an automated production scale ‘Bioreactor’ with capabilities to produce RBC at large scales to end the estimated shortage of 75-90 million units of blood worldwide each year. Heamgen Inc has acquired exclusive license to patent from UCSD to a process of producing and proliferating red blood cells from embryonic stem cells (ESC) in large quantities. Company is founded by leading scientists who have set up the labs at UCSD, UCI, Salk Institute,Sanford Burnham Research Institute Advisory board comprises of Dr.Evan Snyder who is Program Director at Burnham Institute and is considered as one of the fathers of the stem cell field.